Hsbc Holdings PLC Invests $163,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Hsbc Holdings PLC purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 11,658 shares of the company’s stock, valued at approximately $163,000.

Several other institutional investors have also added to or reduced their stakes in DAWN. Quintet Private Bank Europe S.A. grew its stake in shares of Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after acquiring an additional 1,000 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after buying an additional 1,445 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Day One Biopharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after buying an additional 1,447 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Day One Biopharmaceuticals by 67.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 16,817 shares of the company’s stock worth $278,000 after buying an additional 6,750 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals during the 2nd quarter worth $113,000. 87.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DAWN has been the topic of several analyst reports. JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, August 1st. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.71.

Insider Activity

In related news, General Counsel Adam Dubow sold 3,202 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the sale, the general counsel now directly owns 26,928 shares in the company, valued at $376,992. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, insider Samuel C. Blackman sold 2,232 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares of the company’s stock, valued at $15,785,490. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Adam Dubow sold 3,202 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now directly owns 26,928 shares in the company, valued at approximately $376,992. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 68,748 shares of company stock valued at $1,009,272. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Price Performance

Day One Biopharmaceuticals stock opened at $14.10 on Friday. The business has a 50 day moving average of $13.96 and a 200-day moving average of $14.47. The company has a market capitalization of $1.23 billion, a P/E ratio of -5.62 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million. Equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.